





PHARMACEUTICAL 2023

AVADEL PHARMACEUTICALS PLC Rank 368 of 446



The relative strengths and weaknesses of AVADEL PHARMACEUTICALS PLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AVADEL PHARMACEUTICALS PLC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 27% points. The greatest weakness of AVADEL PHARMACEUTICALS PLC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 88% points.

The company's Economic Capital Ratio, given in the ranking table, is -122%, being 165% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	100,843
Cost of Goods Sold	0
Intangible Assets	16,836
Liabilities, Current	55,793
Liabilities, Non-Current	98,137
Other Assets	14,267
Other Compr. Net Income	-2,401
Other Expenses	41,712
Other Liabilities	0
Other Net Income	-536
Other Revenues	0
Property and Equipment	839
Research and Development	20,700
Selling, General and Administrative Expense	74,516

Output Variable	Value in 1000 USD
Assets	132,785
Liabilities	153,930
Expenses	136,928
Revenues	0
Stockholders Equity	-21,145
Net Income	-137,464
Comprehensive Net Income	-138,664
Economic Capital Ratio	-122%